9 of 12 Merkel cell carcinoma patients had virus-specific CD8+ T cells within their tumors, recognizing 1–8 viral epitopes with potential 97% population coverage.
97% coverage16 identified viral epitopes collectively cover 97% of virus-positive Merkel cell carcinoma patients by HLA type
What the researchers found
Tumor-infiltrating lymphocytes from 9 of 12 patients (75%) contained CD8+ T cells that recognized Merkel cell polyomavirus T-antigen. Each patient's immune cells recognized between 1 and 8 different viral epitopes.
Analysis of 16 identified epitopes showed that 97% of patients with virus-positive Merkel cell carcinoma had the HLA alleles needed to mount CD8+ T cell responses against the viral proteins.
The amino acid region 70-110 of the large T antigen was especially rich in immune targets, while the oncogenic domains were not commonly recognized. This is important because a vaccine could focus on the immunogenic region while avoiding the cancer-causing parts.
Why it matters
About half of Merkel cell carcinoma patients respond to immune checkpoint inhibitors. Finding that most tumors already contain virus-specific immune cells suggests the raw ingredients for an immune response are present. A vaccine could boost these existing immune cells.
The fact that immunogenic regions are separate from oncogenic regions means a vaccine could be designed that is both effective and safe, without risk of promoting cancer growth.
The numbers in context
9/12 (75%) had virus-specific TILs; 1-8 epitopes per patient; 16 epitopes mapped; 97% HLA coverage
How the study worked
Researchers extracted tumor-infiltrating lymphocytes from 12 Merkel cell carcinoma patients. They used artificial antigen-presenting cells, synthetic peptides, HLA-peptide tetramers, and dendritic cells to identify which viral epitopes the immune cells recognized. They also analyzed HLA allele coverage across patients.
Who was studied
Merkel cell carcinoma patients (tumor tissue samples)
What this study cannot tell us
This was a small study with only 12 patients. While the HLA coverage analysis extended to a broader population, the direct T cell findings came from a limited sample.
The study did not test whether boosting these T cell responses with a vaccine would actually shrink tumors.
How to read the evidence
Moderate evidence from direct analysis of human tumor-infiltrating lymphocytes. Small patient sample (n=12) but high-quality immunological characterization.
When this study was published
Published in 2020. Therapeutic vaccines for virus-driven cancers continue advancing in clinical trials.
The bigger picture
About half of MCC patients respond to immune checkpoint inhibitors. Finding that most tumors already contain virus-specific immune cells suggests combining checkpoint therapy with a viral peptide vaccine could boost response rates, particularly in non-responders.
Questions still open
- Would a peptide vaccine targeting these epitopes improve checkpoint inhibitor response rates?
- Why do 25% of patients lack detectable virus-specific TILs?
- Can vaccine design safely include viral antigens without oncogenic domains?
Common questions
Why do some cancer tumors contain immune cells?
Could a Merkel cell carcinoma vaccine work?
Read the original research
Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas.
Cancer immunology research, 8(5), 648-659
Citation
Jing, Lichen; Ott, Mariliis; Church, Candice D; Kulikauskas, Rima M; Ibrani, Dafina; Iyer, Jayasri G; Afanasiev, Olga K; Colunga, Aric; Cook, Maclean M; Xie, Hong; Greninger, Alexander L; Paulson, Kelly G; Chapuis, Aude G; Bhatia, Shailender; Nghiem, Paul; Koelle, David M. (2020). Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas.. Cancer immunology research, 8(5), 648-659. https://doi.org/10.1158/2326-6066.CIR-19-0647